Lifordi Immunotherapeutics Secures Strategic Investment From Sanofi Ventures, Raising Total to $112M

Why It Matters

The funding validates the promise of ADC‑based therapies for autoimmune diseases and accelerates Lifordi’s progression toward Phase 2, making it a compelling partner for large pharma. It also gives Sanofi early exposure to a novel drug‑delivery platform that could broaden its immunology pipeline.

Deal Summary

Lifordi Immunotherapeutics announced a new strategic investment from Sanofi Ventures alongside continued support from ARCH Ventures, 5AM Ventures and Atlas Venture. The funding brings the company's total capital raised to $112 million and will back its Phase 1 ADC trial for rheumatoid arthritis. Sanofi Ventures’ principal will join Lifordi’s board as an observer.